Related Experiment Video

Updated: Jun 24, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants

Teresa Guida1, Suresh Anaganti, Livia Provitera

  • 1Istituto di Endocrinologia ed Oncologia Sperimentale del CNR, Dipartimento di Biologia e Patologia Cellulare e Molecolare, Università di Napoli Federico II, Naples, Italy.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|June 5, 2007
PubMed
Abstract

Insights

Sorafenib effectively inhibits gatekeeper mutations in KIT and PDGFRbeta, which cause resistance to imatinib therapy. This multitargeted inhibitor shows promise for treating cancers with these specific kinase mutations.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Imatinib is an effective anticancer drug targeting KIT and PDGFR tyrosine kinases.
  • Gatekeeper mutations (T670 in KIT, T681 in PDGFRbeta) confer resistance to imatinib.
  • Developing new inhibitors for resistant kinase mutants is crucial for cancer therapy.

Purpose of the Study:

  • To evaluate the activity of sorafenib against imatinib-resistant KIT and PDGFRbeta kinases with gatekeeper mutations.
  • To assess sorafenib's efficacy in blocking downstream signaling and cellular proliferation driven by these resistant mutants.

Main Methods:

  • In vitro kinase assays and immunoblots to assess sorafenib's activity on KIT and PDGFRbeta.
  • Reporter luciferase assays to measure downstream signaling.
  • Cell proliferation assays using Ba/F3 cells expressing KIT mutants.

Main Results:

  • Sorafenib potently inhibited KIT T670I (60 nmol/L) and PDGFRbeta T681I (110 nmol/L) gatekeeper mutants.
  • Sorafenib showed less activity against activation loop mutants (KIT D816V, PDGFRbeta D850V).
  • Sorafenib blocked signaling and proliferation in cells with gatekeeper mutations.

Conclusions:

  • Sorafenib demonstrates significant activity against imatinib-resistant KIT and PDGFRbeta gatekeeper mutants.
  • Sorafenib may be a valuable therapeutic option for patients with these specific kinase mutations.
  • Further investigation into sorafenib for gatekeeper mutant-driven cancers is warranted.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...